{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 38,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/19",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.62,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curves for Group A vs Group B",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d777eff-e1cd-4b0a-8649-f928f09a649b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Demonstrated feasibility and clinical benefit of multiple IV cycles; Median 5 prior lines of therapy; Regimen: various dosing levels and schedules; Well tolerated: no-MTD reached with one DLT; Clinical Benefit: statistically significant OS benefit",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63b516af-e9d1-4ce8-ae48-fc5f970fedc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.67,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Group A (n=5; lowest-dose group...); Group B (n=5; highest-dose group...); Groups lowest vs highest TCD: median Overall Survival at 4.6 months vs 20.9 months; p=0.002",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15c5fb87-17e2-44bf-8f79-da4f57ccc42f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Group A (n=11; lower-dose group...); Group B (n=11; higher-dose group...); Groups lower vs higher TCD: median Overall Survival at 4.6 months vs 16.8 months; p=0.026",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf02092d-8acc-436b-b849-9a5b0806ed17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Systemic administration demonstrated dose-dependent OS benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50be9768-6892-4601-aef0-886d128a8d78",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "a5a45b8a-17e8-4f06-b581-6029e995b668",
      "evidence": "list/bullet: Demonstrated feasibility and clinical benefit of multiple IV cycles; Median 5 prior lines of therapy; Regimen: various dosing levels and schedules; Well tolerated: no-MTD reached with one DLT; Clinical Benefit",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 20,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4ce0d94f-89df-47d1-ae65-000e13065e65",
      "evidence": "The presentation highlights the phase 3 pivotal trial design and the encouraging data from the phase 1b trial, showcasing the potential for Olvi-Vec to generate returns for investors.",
      "position": 1,
      "objective": "To present Olvi-Vec as a quick win and a big bet for investors, highlighting its potential for growth and returns",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}